Updates in the Management of Chemotherapy-Induced Nausea and Vomiting

This evidence-based program reviews current CINV guidelines and emerging research, including dexamethasone-sparing regimens and lower-dose olanzapine strategies, with a focus on special populations such as patients with diabetes. Case-based discussions will highlight clinical application, drug interactions, adverse effects, and patient-specific considerations. Learners will engage through interactive polling and receive a summary handout on antiemetic management.

Learning Objectives:

At the completion of this session, pharmacists will be able to:
1. Identify patient- and treatment-related risk factors for CINV.
2. Evaluate the appropriateness of antiemetic regimens for common chemotherapy protocols.
3. Compare antiemetic toxicities and select optimal therapy based on patient-specific factors.
4. Design antiemetic regimens for commonly used cancer treatments.
5. Develop evidence-based recommendations for patient-specific treatment plans.

At the completion of this program, technicians will be able to:
1. Identify patient- and treatment-related risk factors for CINV.
2. List antiemetic regimens for common chemotherapy protocols.
3. Describe antiemetic toxicities and therapies based on patient-specific factors.
4. List antiemetic regimens for commonly used cancer treatments.

Texas Pharmacy Association (154) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Continuing education will be provided to participants who completed all course requirements.
ACPE 0154-0000-26-007-H01-P
ACPE 0154-0000-26-007-H01-T
1 Contact Hour (0.1 CEU)
Knowledge-based